REMD-456A / REMD Bio - LARVOL DELTA

Targeted optimized interferon alpha demonstrates improved safety and efficacy in tumors with low PD-L1 expression (AACR 2025) - "REMD-456 was selected for its efficacy and safety profile in vitro and in vivo and manufacturability. It showed enhanced IFN activity only on PD-L1+ cells, resulting in an improved therapeutic window. In vivo, REMD-456 demonstrated superior anti-tumor efficacy in human tumor xenografts."

Clinical • IO biomarker • Oncology • IFNA1 • IFNAR1 • PD-L1